CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Rock Creek Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Rock Creek Pharmaceuticals Inc
Suite 300, 2040 Whitfield Avenue
Phone: (804) 527-1970p:804 527-1970 SARASOTA, FL  34243  United States Fax: (302) 636-5454f:302 636-5454
This company is no longer actively traded on any major stock exchange.
Business Summary
Rock Creek Pharmaceuticals, Inc. is a pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. The Company's activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine. The Company has completed Phase I safety studies of its product candidate in Europe. In pre-clinical testing, anatabine demonstrates anti-inflammatory activity in a range of in vitro and in vivo assays.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201612/31/2015YesYesYes-Yes

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Office of President, Chief Executive Officer Michael J.Mullan 59 6/9/2015 12/27/2013
Chief Financial Officer William L.McMahon 64 8/14/2015 8/14/2015
Secretary, Vice President - Corporate Strategy & Development TheodoreJenkins 8/14/2015 8/14/2015
Independent Director Lee M.Canaan 65 8/1/2014 8/1/2014
Independent Director Robert W.Scannell 57 11/19/2015 11/19/2015

Business Names
Business Name
RCP Development, Inc.
RCPI
RCPIQ
Star Pharma, Inc.
Star Scientific, Inc.
Star Tobacco, Inc.

General Information
Number of Employees: 10 (As of 12/31/2014)
Outstanding Shares: 170,444,758 (As of 8/3/2016)
Shareholders: 597
Stock Exchange: OTC
Federal Tax Id: 521402131
Fax Number: (302) 636-5454
Email Address: webmaster@starscientific.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023